Lifespot Health has recorded the first sales of its medicinal cannabis inhaler to Australian patients under the Special Access Scheme.
The company launched its Medihale sealed pod inhaler device in Melbourne, with the first patients using it with third-party EC Pharma’s CBD e-liquid.
Lifespot chief executive officer Matthew Golden told Small Caps feedback from patients has been “very positive” due to the fast onset, ease of use, portability and discrete nature of the product.
Oxford Cannabinoid Technologies
Snoop Dogg-backed cannabis research firm Oxford Cannabinoid Technologies (OCT) has listed on the London Stock Exchange.
The initial public offering was expected to raise £16.5 million with OCT’s valuation after listing tipped to be £51.5 million.
The company focuses on developing pain relief treatments using cannabinoids and has four potential drugs in the pipeline. It will use the funds to prepare drug candidates for clinical trials starting next year.
Snoop Dogg has a 3.2% stake in OCT via his venture capital vehicle Casa Verde.
ECS Botanics has launched a range of specially formulated CB1 and CB2 terpene blends under its wellness brand, using Tasmanian cannabis sativa seed oil.
The company has signed a non-exclusive distribution agreement with Cronos Australia to resell the range and is in discussions with other partners to broaden its reach across Australia.
Creso Pharma has signed an agreement with Polish company Polvet to distribute the company’s Anibidiol range for the management of stress in, and well being of, pets and livestock. The agreement marks the company’s first entry into Eastern Europe.